Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy

Indication
IgG4 Related Disease

Other upcoming events for ZBIO

Phase 2 ReadoutPhase 2 Readout: obexelimab
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety
Phase 2 ReadoutPhase 2 Readout: obexelimab
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy — ZBIO Phase 3 Readout | BioSniper